For decades, the medical world has avidly searched for groundbreaking treatments against one of humanity’s most resilient foes: cancer. Today, that search might be inching closer to a significant discovery, as a recent phase I clinical trial of PAC-1 has exhibited potential to combat various cancer types, revealing only minor side effects. PAC-1, a drug originally developed by scientists at the University of Illinois Urbana-Champaign, triggers programmed cell death in cancer cells. Most notably, it managed to halt tumor growth in five participants suffering from neuroendocrine cancers. Impress…